Won-Seog Kim

1.7k total citations
37 papers, 785 citations indexed

About

Won-Seog Kim is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Won-Seog Kim has authored 37 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 25 papers in Oncology and 13 papers in Immunology. Recurrent topics in Won-Seog Kim's work include Lymphoma Diagnosis and Treatment (31 papers), CAR-T cell therapy research (12 papers) and Viral-associated cancers and disorders (8 papers). Won-Seog Kim is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), CAR-T cell therapy research (12 papers) and Viral-associated cancers and disorders (8 papers). Won-Seog Kim collaborates with scholars based in South Korea, United States and Spain. Won-Seog Kim's co-authors include Young Hyeh Ko, Yok‐Lam Kwong, Ranjana H. Advani, Kensei Tobinai, Françoise Berger, Randy D. Gascoyne, Elaine S. Jaffe, Stefano Pileri, Shigeo Nakamura and Kerry J. Savage and has published in prestigious journals such as Blood, The Lancet Oncology and Journal of Nuclear Medicine.

In The Last Decade

Won-Seog Kim

34 papers receiving 775 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Won-Seog Kim South Korea	14	635	484	281	170	114	37	785
Neha Mehta–Shah United States	16	551 0.9×	433 0.9×	294 1.0×	312 1.8×	99 0.9×	94	878
Won-Seog Kim South Korea	6	696 1.1×	580 1.2×	250 0.9×	118 0.7×	100 0.9×	8	796
Santiago Mercadal Spain	12	567 0.9×	403 0.8×	158 0.6×	104 0.6×	235 2.1×	56	710
Liuyan Jiang United States	13	379 0.6×	284 0.6×	164 0.6×	119 0.7×	123 1.1×	79	666
TC Greiner United States	8	709 1.1×	454 0.9×	176 0.6×	85 0.5×	317 2.8×	10	824
Sang Eun Yoon South Korea	16	475 0.7×	537 1.1×	259 0.9×	57 0.3×	110 1.0×	102	949
P Korbjuhn Germany	9	867 1.4×	779 1.6×	298 1.1×	149 0.9×	222 1.9×	12	1.1k
Alvaro J. Alencar United States	10	369 0.6×	241 0.5×	162 0.6×	114 0.7×	118 1.0×	58	691
Eulogio Conde Spain	15	534 0.8×	408 0.8×	177 0.6×	117 0.7×	186 1.6×	43	869
C Gisselbrecht France	15	543 0.9×	451 0.9×	177 0.6×	111 0.7×	181 1.6×	36	860

Countries citing papers authored by Won-Seog Kim

Since Specialization

Citations

This map shows the geographic impact of Won-Seog Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Won-Seog Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Won-Seog Kim more than expected).

Fields of papers citing papers by Won-Seog Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Won-Seog Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Won-Seog Kim. The network helps show where Won-Seog Kim may publish in the future.

Co-authorship network of co-authors of Won-Seog Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Won-Seog Kim. A scholar is included among the top collaborators of Won-Seog Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Won-Seog Kim. Won-Seog Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldstein, Jordan, Mark Roschewski, Won-Seog Kim, et al.. (2024). Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL. Blood. 144(Supplement 1). 651–651.

Allan, John N., Jennifer L. Crombie, Matthew J. Matasar, et al.. (2024). Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies. Blood. 144(Supplement 1). 3118–3118. 3 indexed citations

Kim, Won-Seog, Tae Min Kim, Seok‐Goo Cho, et al.. (2022). Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2. Blood. 140(Supplement 1). 1070–1071. 24 indexed citations

Buske, Christian, Wojciech Jurczak, Juan‐Manuel Sancho, et al.. (2021). Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. Blood Advances. 5(17). 3354–3361. 6 indexed citations

Budde, Lihua E., Laurie H. Sehn, Sarit Assouline, et al.. (2018). Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. Blood. 132(Supplement 1). 399–399. 44 indexed citations

Sehn, Laurie H., Alex F. Herrera, Matthew J. Matasar, et al.. (2018). Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. Blood. 132(Supplement 1). 1683–1683. 15 indexed citations

Kim, Won-Seog, et al.. (2018). Similar Efficacy and Safety of CT-P10 and Reference Rituximab in Patients with Advanced Stage Follicular Lymphoma: Updated Phase III Study Results. Blood. 132(Supplement 1). 1616–1616. 4 indexed citations

Witzig, Thomas E., Lubomir Sokol, Eric D. Jacobsen, et al.. (2018). Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood. 132(Supplement 1). 2937–2937. 2 indexed citations

Kim, Won-Seog, Hyeon‐Seok Eom, Su‐Peng Yeh, et al.. (2018). Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study. Blood. 132(Supplement 1). 1617–1617. 7 indexed citations

10.

Son, Seung-Myoung, et al.. (2016). Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression. Modern Pathology. 30(1). 4–14. 16 indexed citations

11.

Hong, Min Eui, et al.. (2016). Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior. Modern Pathology. 29(5). 430–443. 37 indexed citations

12.

Tan, Daryl, Soo‐Yong Tan, Soon Thye Lim, et al.. (2013). Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. The Lancet Oncology. 14(12). e548–e561. 24 indexed citations

13.

Moon, Seung Hwan, Won-Seog Kim, Yong Chan Ahn, et al.. (2013). The Role of¹⁸F-FDG PET/CT for Initial Staging of Nasal Type Natural Killer/T-Cell Lymphoma: A Comparison with Conventional Staging Methods. Journal of Nuclear Medicine. 54(7). 1039–1044. 52 indexed citations

14.

Ahn, Jin‐Seok, et al.. (2009). The Fluorescence Immunoassay of lung Cancer Serum Diomarkers using Quantum dots. Journal of Biomedical Engineering Research. 30(2). 122–128. 1 indexed citations

15.

Kwong, Yok‐Lam, Benjamin O. Anderson, Ranjana H. Advani, et al.. (2009). Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology. 10(11). 1093–1101. 78 indexed citations

16.

Yoo, Eun‐Hyung, Hee‐Jin Kim, Seung‐Tae Lee, Won-Seog Kim, & Sun‐Hee Kim. (2009). Frequent CD7 Antigen Loss in Aggressive Natural Killer-Cell Leukemia: A Useful Diagnostic Marker. Annals of Laboratory Medicine. 29(6). 491–496. 7 indexed citations

17.

Kım, Kihyun, et al.. (2008). The Spectrum of Epstein-Barr Virus-Associated Lymphoproliferative Disease in Korea: Incidence of Disease Entities by Age Groups. Journal of Korean Medical Science. 23(2). 185–185. 42 indexed citations

18.

Ko, Young Hyeh, Won-Seog Kim, & Yoonjung Kim. (2005). Expression of CD56 antigen in Langerhans cell histiocytosis associated with T-lymphoblastic lymphoma in a same lymph node. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 448(1). 90–94. 3 indexed citations

19.

Sung, Chang Ohk, Young Hyeh Ko, Sang‐Hui Park, Kihyun Kım, & Won-Seog Kim. (2005). Immunoreactivity of CD99 in Non-Hodgkin's Lymphoma: Unexpected Frequent Expression in ALK-positive Anaplastic Large Cell Lymphoma. Journal of Korean Medical Science. 20(6). 952–952. 15 indexed citations

20.

Park, Chaehwa, et al.. (2002). Effects of transforming growth factor β (TGF-β) receptor on lung carcinogenesis. Lung Cancer. 38(2). 143–147. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact